149 related articles for article (PubMed ID: 22384355)
1. The SPRED1 Variants Repository for Legius Syndrome.
Sumner K; Crockett DK; Muram T; Mallempati K; Best H; Mao R
G3 (Bethesda); 2011 Nov; 1(6):451-6. PubMed ID: 22384355
[TBL] [Abstract][Full Text] [Related]
2. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome.
Messiaen L; Yao S; Brems H; Callens T; Sathienkijkanchai A; Denayer E; Spencer E; Arn P; Babovic-Vuksanovic D; Bay C; Bobele G; Cohen BH; Escobar L; Eunpu D; Grebe T; Greenstein R; Hachen R; Irons M; Kronn D; Lemire E; Leppig K; Lim C; McDonald M; Narayanan V; Pearn A; Pedersen R; Powell B; Shapiro LR; Skidmore D; Tegay D; Thiese H; Zackai EH; Vijzelaar R; Taniguchi K; Ayada T; Okamoto F; Yoshimura A; Parret A; Korf B; Legius E
JAMA; 2009 Nov; 302(19):2111-8. PubMed ID: 19920235
[TBL] [Abstract][Full Text] [Related]
3. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
[TBL] [Abstract][Full Text] [Related]
4. Legius Syndrome and Inflammatory Bowel Disease: A Pediatric Case Report.
Paixao F; Ribeiro L; Costa A; Torre M; Ventura A
Cureus; 2023 Oct; 15(10):e46394. PubMed ID: 37927732
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic Mutations Associated with Legius Syndrome Modify the Spred1 Surface and Are Involved in Direct Binding to the Ras Inactivator Neurofibromin.
Führer S; Tollinger M; Dunzendorfer-Matt T
J Mol Biol; 2019 Sep; 431(19):3889-3899. PubMed ID: 31401120
[TBL] [Abstract][Full Text] [Related]
6. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1.
Brems H; Legius E
Keio J Med; 2013; 62(4):107-12. PubMed ID: 24334617
[TBL] [Abstract][Full Text] [Related]
7. Café-au-lait macules and intertriginous freckling in piebaldism: clinical overlap with neurofibromatosis type 1 and Legius syndrome.
Stevens CA; Chiang PW; Messiaen LM
Am J Med Genet A; 2012 May; 158A(5):1195-9. PubMed ID: 22438235
[TBL] [Abstract][Full Text] [Related]
8. Legius Syndrome and its Relationship with Neurofibromatosis Type 1.
Denayer E; Legius E
Acta Derm Venereol; 2020 Mar; 100(7):adv00093. PubMed ID: 32147744
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive RNA Analysis of the NF1 Gene in Classically Affected NF1 Affected Individuals Meeting NIH Criteria has High Sensitivity and Mutation Negative Testing is Reassuring in Isolated Cases With Pigmentary Features Only.
Evans DG; Bowers N; Burkitt-Wright E; Miles E; Garg S; Scott-Kitching V; Penman-Splitt M; Dobbie A; Howard E; Ealing J; Vassalo G; Wallace AJ; Newman W; ; Huson SM
EBioMedicine; 2016 May; 7():212-20. PubMed ID: 27322474
[TBL] [Abstract][Full Text] [Related]
10. Family with Legius syndrome (neurofibromatosis type 1-like syndrome).
Sakai N; Maeda T; Kawakami H; Uchiyama M; Harada K; Tsuboi R; Mitsuhashi Y
J Dermatol; 2015 Jul; 42(7):703-5. PubMed ID: 25981987
[TBL] [Abstract][Full Text] [Related]
11. SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.
Pasmant E; Gilbert-Dussardier B; Petit A; de Laval B; Luscan A; Gruber A; Lapillonne H; Deswarte C; Goussard P; Laurendeau I; Uzan B; Pflumio F; Brizard F; Vabres P; Naguibvena I; Fasola S; Millot F; Porteu F; Vidaud D; Landman-Parker J; Ballerini P
Oncogene; 2015 Jan; 34(5):631-8. PubMed ID: 24469042
[TBL] [Abstract][Full Text] [Related]
12. [A novel neurocutaneous syndrome: Legius syndrome. A case report].
Cemeli-Cano M; Peña-Segura JL; Fernando-Martínez R; Izquierdo-Álvarez S; Monge-Galindo L; López-Pisón J
Rev Neurol; 2014 Sep; 59(5):209-12. PubMed ID: 25156025
[TBL] [Abstract][Full Text] [Related]
13. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype.
Pasmant E; Sabbagh A; Hanna N; Masliah-Planchon J; Jolly E; Goussard P; Ballerini P; Cartault F; Barbarot S; Landman-Parker J; Soufir N; Parfait B; Vidaud M; Wolkenstein P; Vidaud D; France RN
J Med Genet; 2009 Jul; 46(7):425-30. PubMed ID: 19366998
[TBL] [Abstract][Full Text] [Related]
14. Association of Piebaldism, multiple café-au-lait macules, and intertriginous freckling: clinical evidence of a common pathway between KIT and sprouty-related, ena/vasodilator-stimulated phosphoprotein homology-1 domain containing protein 1 (SPRED1).
Chiu YE; Dugan S; Basel D; Siegel DH
Pediatr Dermatol; 2013; 30(3):379-82. PubMed ID: 23016555
[TBL] [Abstract][Full Text] [Related]
15. Lisch nodules and iris mammillations in two siblings with familial legius syndrome.
Bixel KD; Cano MJ; Johnson DM; Gomez B; Lobsinger LV; Valentin FE; Hsieh DT; Rohena LO
Clin Case Rep; 2020 Oct; 8(10):1867-1871. PubMed ID: 33088508
[TBL] [Abstract][Full Text] [Related]
16. Review and update of SPRED1 mutations causing Legius syndrome.
Brems H; Pasmant E; Van Minkelen R; Wimmer K; Upadhyaya M; Legius E; Messiaen L
Hum Mutat; 2012 Nov; 33(11):1538-46. PubMed ID: 22753041
[TBL] [Abstract][Full Text] [Related]
17. Epilepsy in Legius syndrome: Coincidence or causation?
Medina Lemus A; Boelman C; Myers KA
Am J Med Genet A; 2024 Jun; 194(6):e63547. PubMed ID: 38268057
[TBL] [Abstract][Full Text] [Related]
18. Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.
Witkowski L; Dillon MW; Murphy E; S Lebo M; Mason-Suares H
Mol Genet Genomic Med; 2020 Apr; 8(4):e1180. PubMed ID: 32107864
[TBL] [Abstract][Full Text] [Related]
19. Identification of SPRED1 deletions using RT-PCR, multiplex ligation-dependent probe amplification and quantitative PCR.
Spencer E; Davis J; Mikhail F; Fu C; Vijzelaar R; Zackai EH; Feret H; Meyn MS; Shugar A; Bellus G; Kocsis K; Kivirikko S; Pöyhönen M; Messiaen L
Am J Med Genet A; 2011 Jun; 155A(6):1352-9. PubMed ID: 21548021
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
